Form 4: Neurocrine CEO Kyle Gano Reports Stock Transactions

Neurocrine Biosciences CEO Kyle Gano reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Kyle Gano, CEO and Director of Neurocrine Biosciences Inc. (NBIX), reported transactions involving the company's common stock.
• On November 1, 2025, 613 Restricted Stock Units (RSUs) vested, converting into 613 shares of common stock at a price of $0.
• Following this vesting, Gano's direct beneficial ownership of common stock increased to 140,720 shares.
• On November 4, 2025, Gano sold 300 shares of common stock at a price of $141.97 per share.
• This sale was mandatory and conducted to cover withholding taxes and tax-related items associated with the RSU vesting, in accordance with a Rule 10b5-1(c) plan.
• After the sale, Gano's direct beneficial ownership of common stock is 140,407 shares.
• Gano also holds 1,842 unvested Restricted Stock Units.
• Future RSU vesting dates include 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events (RSU vesting) and a standard tax-related stock sale. While a sale reduces direct ownership, it's a common and expected part of equity compensation. The continued significant beneficial ownership and future vesting schedule are positive for management alignment.

Positives

• Vesting of 613 Restricted Stock Units (RSUs) on November 1, 2025, indicating compensation realization for the CEO.
• Continued significant beneficial ownership of 140,407 shares of common stock by the CEO, aligning management interests with shareholders.
• Future vesting schedule for 1,842 additional RSUs (614 shares annually from 2026-2028) provides long-term incentive.

Negatives

• Sale of 300 shares of common stock on November 4, 2025, reducing direct beneficial ownership.
• The sale was mandatory to cover tax obligations, which is a common practice but still represents a reduction in direct holdings.

Future Outlook

The filing indicates future vesting of 1,842 Restricted Stock Units for Kyle Gano, with 614 shares scheduled to vest annually on November 1st from 2026 through 2028, subject to award terms.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide broader industry context or trends. It reflects standard executive compensation practices within the biotechnology or pharmaceutical sector, where equity awards like RSUs are common.

Comparison to Industry Standards

• This filing details routine executive compensation and tax-related stock sales, which are standard practices across publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• The use of Rule 10b5-1 plans for pre-scheduled sales to cover tax obligations is a common corporate governance practice designed to mitigate concerns about insider trading.
• The structure of RSU grants with multi-year vesting schedules is typical for executive incentive programs, aiming to align long-term interests between executives and shareholders.

Corporate Governance

Related Party Transactions

• The transactions involve the CEO and the company's equity, which are standard related-party dealings in the context of executive compensation. The sale was to cover taxes related to RSU vesting from the issuer.

Stakeholder Impact

• Shareholders: The CEO's continued significant beneficial ownership (140,407 shares) and future RSU vesting align his interests with long-term shareholder value. The tax-related sale is a minor, routine reduction in holdings.
• Employees: The filing indirectly highlights the company's equity compensation structure, which can be a factor in employee retention and motivation.

Next Steps

• Future vesting of 614 Restricted Stock Units on November 1, 2026.
• Future vesting of 614 Restricted Stock Units on November 1, 2027.
• Future vesting of 614 Restricted Stock Units on November 1, 2028.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically RSU vesting and a tax-related stock sale under a 10b5-1 plan. Such transactions are generally expected and do not typically indicate a change in the company's fundamental outlook or the executive's confidence. The CEO maintains a substantial beneficial ownership, and future RSU vesting provides continued alignment. Therefore, based solely on this filing, a "hold" recommendation is appropriate as there's no new information to warrant a change in investment thesis.

Keywords

Neurocrine Biosciences, NBIX, Kyle Gano, SEC Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Executive Compensation, Rule 10b5-1, Beneficial Ownership